Turkish Validity and Reliability of the Parkinson's Disease Neuropsychometric Dementia Assessment Questionnaire in Individuals With Parkinson's Disease

NCT07815964 | Not Yet Recruiting

• 1 other identifier: 2026-10/436
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to examine the validity and reliability of the Turkish version of the Parkinson's Neuropsychometric Dementia Assessment (PANDA) in individuals with Parkinson's disease. This cross-sectional methodological study will evaluate the psychometric properties of the Turkish PANDA, including internal consistency, test-retest reliability, and construct validity, in order to provide a valid and reliable instrument for the assessment of cognitive impairment and dementia-related cognitive changes in Turkish-speaking individuals with Parkinson's disease.

Conditions

PARKINSON DISEASE (Disorder)

Keywords

Parkinson's disease; Rehabilitation

Outcome Measures

Primary Outcomes (1)

• Parkinson Neuropsychometric Dementia Assessment (PANDA) Total Score

  Cognitive performance will be assessed using the Turkish version of the Parkinson's Neuropsychometric Dementia Assessment (PANDA) in individuals with Parkinson's disease. The PANDA is a brief cognitive screening instrument specifically developed for Parkinson's disease and includes tasks assessing learning and memory, verbal fluency, visuospatial processing, working memory, and delayed recall. The PANDA total score ranges from 0 to 30, with higher scores indicating better cognitive performance. The psychometric properties of the Turkish version, including internal consistency, test-retest reliability, and construct validity, will be evaluated.

  [Time Frame: Baseline (at the time of PANDA administration)]

Secondary Outcomes (2)

• Montreal Cognitive Assessment (MoCA) Total Score

  [Time Frame: Baseline (at the time of cognitive assessment)]

• Mini-Mental State Examination (MMSE) Total Score

  [Time Frame: Baseline (at the time of cognitive assessment)]

Study Arms (1)

Parkinson's Disease

Other: Parkinson Neuropsychometric Dementia Assessment

Interventions

Parkinson Neuropsychometric Dementia Assessment OTHER

Participants will complete the Turkish version of the Parkinson Neuropsychometric Dementia Assessment (PANDA) as part of the psychometric evaluation process. The PANDA will be administered according to standardized instructions to assess cognitive performance in individuals with Parkinson's disease. To evaluate test-retest reliability, the Turkish PANDA will be re-administered to a subgroup of participants after a predefined interval under similar conditions. No therapeutic intervention will be provided as part of this methodological validation study.

Parkinson's Disease

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will consist of individuals with clinically diagnosed Parkinson's disease (Hoehn and Yahr stage 1-3), aged between 40 and 85 years, with adequate cognitive function (MMSE ≥ 24). Participants will be recruited from patients attending the Movement Disorders Outpatient Clinic of the Neurology Department. The study population represents ambulatory individuals with mild to moderate disease severity suitable for comprehensive biopsychosocial assessment.

You may qualify if:

• Clinical diagnosis of Parkinson's disease
• Hoehn and Yahr stage 1-3
• Age between 40 and 85 years
• Mini-Mental State Examination score ≥ 24
• Sufficient cognitive and communication ability to complete the assessments
• Attendance at the Movement Disorders Outpatient Clinic of the Neurology Department
• Willingness to participate in the study and provide written informed consent

You may not qualify if:

• Presence of a major psychiatric disorder, such as major depressive disorder or a psychotic disorder
• Diagnosis of advanced dementia
• Presence of an uncontrolled systemic chronic disease, such as uncontrolled diabetes mellitus or hypertension
• Presence of a severe cardiovascular or respiratory condition
• Presence of an additional orthopedic or neurological condition that may affect assessment performance
• Severe visual or hearing impairment that may interfere with the assessments
• Inability to cooperate adequately during the assessments

Sponsors & Collaborators

• Acibadem University: lead

Study Sites (1)

Acibadem University

Istanbul, Turkey, +90, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Central Study Contacts

Nuray Alaca Alaca, Prof. Dr

CONTACT

05324251290; nuraygeceralaca@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof. Dr

Study Record Dates

• First Submitted: September 7, 2026
• First Posted: September 11, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): July 1, 2027
• Last Updated: September 14, 2026

Record last verified: 2026-09

Locations

TU (1)